| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-10-23 |
复牌提示：
2020-10-22 19:50:13 停牌，复牌日期 2020-10-26 00:00:01
|
| 2020-10-23 |
详情>>
内部人交易：
BAUM CHARLES M等共交易9笔
|
| 2020-08-05 |
详情>>
股本变动：
变动后总股本23114.35万股
|
| 2020-08-05 |
财报披露：
美东时间 2020-08-05 盘后发布财报
|
| 2020-08-05 |
详情>>
业绩披露：
2020年中报每股收益-0.73美元,归母净利润-1.6亿美元,同比去年增长2.31%
|
| 2020-05-06 |
详情>>
业绩披露：
2020年一季报每股收益-0.44美元,归母净利润-9304.7万美元,同比去年增长-6.54%
|
| 2020-04-27 |
股东大会：
将于2020-06-18召开股东大会
会议内容 ▼▲
- 1.Elect 8 directors to serve for a term of one year until the 2021 Annual Meeting of Stockholders;
2.Approve, on an advisory basis, the compensation of our named executive officers;
3.Approve the amendment and restatement of the Company's certificate of incorporation, as amended, to increase the maximum number of authorized shares of the Company's capital stock, all classes, from 260,000,000 shares, consisting of (i) 250,000,000 shares of common stock, $0.01 par value per share ("Common Stock"), and (ii) 10,000,000 shares of preferred stock, $0.01 par value per share ("Preferred Stock"), to 285,000,000 shares, consisting of (x) 275,000,000 shares of Common Stock, and (y) 10,000,000 shares of Preferred Stock;
4.Approve the amendment and restatement of the Immunomedics, Inc. 2014 Long-Term Incentive Plan;
5.Approve the Immunomedics, Inc. 2020 Employee Stock Purchase Plan;
6.Ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2020;
7.Consider any other business as may properly come before the Annual Meeting or any postponement or adjournment of the meeting.
|
| 2020-02-27 |
详情>>
业绩披露：
2019年年报每股收益-1.84美元,归母净利润-3.57亿美元,同比去年增长-30.44%
|
| 2019-10-30 |
详情>>
业绩披露：
2018年三季报(累计)每股收益-1.24美元,归母净利润-2.17亿美元,同比去年增长-116.85%
|
| 2019-04-30 |
股东大会：
将于2019-06-07召开股东大会
会议内容 ▼▲
- 1.Elect 6 directors to serve for a term of one year until the 2020 Annual Meeting of Stockholders;
2.Approve, on an advisory basis, the compensation of our named executive officers;
3.Ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2019;
4.Consider any other business as may properly come before the Annual Meeting or any postponement or adjournment of the meeting.
|
| 2019-02-25 |
详情>>
业绩披露：
2017年年报每股收益-1.47美元,归母净利润-1.53亿美元,同比去年增长-159.51%
|
| 2018-11-07 |
详情>>
业绩披露：
2019年一季报每股收益-0.34美元,归母净利润-6416.9万美元,同比去年增长-80.52%
|
| 2018-08-23 |
详情>>
业绩披露：
2018年年报每股收益-1.78美元,归母净利润-2.74亿美元,同比去年增长-78.74%
|
| 2018-03-02 |
股东大会：
将于2018-04-02召开股东大会
会议内容 ▼▲
- 1.Elect five directors to serve for a term of one year until the 2018 Annual Meeting of Stockholders;
2.Approve, on an advisory basis, compensation of our named executive officers;
3.To determine, on an advisory basis, the frequency with which the stockholders of the Company shall have an advisory vote on executive compensation;
4.Ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2018;
5.Consider any other business as may properly come before the Annual Meeting or any postponement or adjournment of the meeting.
|
| 2017-01-09 |
股东大会：
将于2017-03-03召开股东大会
会议内容 ▼▲
- 1.to elect seven director nominees, Jason M. Aryeh, Dr. Geoffrey Cox, Robert Forrester, Dr. David M. Goldenberg, Brian A. Markison, Bob Oliver and Cynthia L. Sullivan, or any others properly nominated to serve until the 2017 Annual Meeting of Stockholders and until their successors are duly elected;
2.to approve, on an advisory basis, the compensation of our named executive officers;
3.to approve the amendment and restatement of our certificate of incorporation, as amended, to increase the maximum number of authorized shares of the Company’s capital stock, all classes, from 165,000,000 shares, consisting of (i) 155,000,000 shares of common stock, $0.01 par value per share (“Common Stock”), and (ii) 10,000,000 shares of preferred stock, $0.01 par value per share (“Preferred Stock”), to 205,000,000 shares, consisting of (A) 195,000,000 shares of Common Stock, and (B) 10,000,000 shares of Preferred Stock;
4.to ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2017;
5.to consider any other business as may properly come before the 2016 Annual Meeting or any postponement or adjournment thereof.
|
| 2015-10-21 |
股东大会：
将于2015-12-02召开股东大会
会议内容 ▼▲
- 1.Elect six directors to serve for a term of one year until the 2016 Annual Meeting of Stockholders;
2.Approve, on an advisory basis, compensation of our named executive officers;
3.Ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2016;
4.Consider any other business as may properly come before the Annual Meeting or any postponement or adjournment of the meeting.
|
| 2014-10-22 |
股东大会：
将于2014-12-03召开股东大会
会议内容 ▼▲
- 1.Elect six directors to serve for a term of one year until the 2015 Annual Meeting of Stockholders;
2.Approve, on an advisory basis, compensation of the company's named executive officers;
3.Approve the amendment and restatement of the Company’s certificate of incorporation, as amended, to increase the maximum number of authorized shares of the Company’s capital stock, all classes, from 145,000,000 shares, consisting of (i) 135,000,000 shares of common stock, $0.01 par value per share ("Common Stock"), and (ii) 10,000,000 shares of preferred stock, $0.01 par value per share ("Preferred Stock"), to 165,000,000 shares, consisting of (x) 155,000,000 shares of Common Stock, and (y) 10,000,000 shares of Preferred Stock;
4.Approve the Immunomedics, Inc. 2014 Long-Term Incentive Plan;
5.Ratify the selection by the Audit Committee of the company's Board of Directors of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending June 30, 2015;
6.Consider any other business as may properly come before the Annual Meeting or any postponement or adjournment of the meeting.
|
| 2013-10-25 |
股东大会：
将于2013-12-04召开股东大会
会议内容 ▼▲
- 1. Elect six directors to serve for a term of one year until the 2014 Annual Meeting of Stockholders;
2. To approve the Company’s named executive officers’ compensation on an advisory basis;
3. Ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2014;
4. Consider any other business as may properly come before the Annual Meeting or any postponement or adjournment of the meeting.
|
| 2012-10-24 |
股东大会：
将于2012-12-05召开股东大会
会议内容 ▼▲
- 1.Elect seven directors to serve for a term of one year until the 2013 Annual Meeting of Stockholders
2.To approve the Company’s named executive officers’ compensation on an advisory basis
3.To approve the amendment and restatement of the Company’s certificate of incorporation, as amended, to increase the maximum number of authorized shares of the Company’s capital stock, all classes, from 120,000,000 shares, consisting of (i) 110,000,000 shares of common stock, $0.01 par value per share (“Common Stock”), and (ii) 10,000,000 shares of preferred stock, $0.01 par value per share (“Preferred Stock”), to 145,000,000 shares, consisting of (x) 135,000,000 shares of Common Stock, and (y) 10,000,000 shares of Preferred Stock
4.Ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2013
5.Consider any other business as may properly come before the Annual Meeting or any postponement or adjournment of the meeting.
|